Skip to main content

Table 1 Formulation and physicochemical evaluation of pirfenidone nanoparticles

From: Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis

Batch

Drug (mg)

CS (mg)

MPS (nm)

ZP (mV)

Charge

PDI

% Yield

% EE

% DR8

% DR12

F1

0

100

239.3 ± 1.8

35.0 ± 1.2

strongly cationic

0.181 ± 0.010

56

0

−

−

F2

100

50

248.6 ± 1.4

32.5 ± 1.4

strongly cationic

0.191 ± 0.012

60

17.00 ± 2.0

92.15 ± 2.04

98.94 ± 2.49

F3

100

100

440.8 ± 3.9

36.3 ± 0.8

strongly cationic

0.121 ± 0.062

55.5

23.76 ± 1.8

86.53 ± 3.04

95.25 ± 2.89

F4

100

150

549.1 ± 0.3

37.7 ± 1.4

strongly cationic

0.205 ± 0.023

56.33

34.98 ± 4.7

84.21 ± 2.53

92.34 ± 2.49

F5

100

200

687.8 ± 4.3

34.4 ± 1.8

strongly cationic

0.240 ± 0.030

51.33

39.60 ± 4.0

82.43 ± 1.49

90.21 ± 1.35

F6

100

250

803.4 ± 2.6

35.7 ± 0.5

strongly cationic

0.344 ± 0.024

59.33

61.20 ± 7.0

81.67 ± 1.36

87.66 ± 1.36

F7

100

300

928.7 ± 4.6

38.9 ± 1.0

strongly cationic

0.481 ± 0.022

54.33

60.48 ± 4.3

79.78 ± 2.47

85.36 ± 2.16

  1. Mean particle size (nm), Polydispersity index (PDI), Zeta Potential (mV), % Drug entrapment efficiency (EE), % Drug Release at 8 h., and % Drug Release at 12 h. Mean ± SD. N = 3